Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up on Analyst Upgrade

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price gapped up before the market opened on Wednesday after JonesTrading raised their price target on the stock from $74.00 to $90.00. The stock had previously closed at $40.91, but opened at $47.51. JonesTrading currently has a buy rating on the stock. Definium Therapeutics shares last traded at $42.85, with a volume of 2,741,718 shares traded.

DFTX has been the topic of a number of other reports. Wall Street Zen cut Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Oppenheimer reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Wednesday. Canaccord Genuity Group set a $64.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Finally, Wells Fargo & Company boosted their target price on Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $62.69.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares in the company, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 48,096 shares of company stock valued at $2,165,763 in the last ninety days. Company insiders own 2.40% of the company’s stock.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: DT120 met its Phase 3 GAD objectives. Definium reported positive topline results from the Voyage study, with DT120 ODT producing a 5.4-point improvement on the Hamilton Anxiety Rating Scale versus placebo. The late-stage result strengthens the potential for DT120 to become a commercially important anxiety treatment. Definium Therapeutics Hits Phase 3 GAD Goals for DT120 ODT
• Positive Sentiment: Analysts raised their valuations following the trial update. JonesTrading increased its price target to $90 and maintained a “buy” rating. RBC raised its target to $66 with an “outperform” rating, while Wells Fargo lifted its target to $72 and kept an “overweight” rating. Baird raised its target to $75 and Needham increased its target to $66; all cited the improving outlook for DT120. RBC Comments on Definium Therapeutics DT120 Data
• Positive Sentiment: Investor confidence in future development has improved. RBC said the DT120 data increases confidence in subsequent trials and supports the company’s plans across two potential indications. The results follow another positive Phase 3 study, giving investors additional evidence that the program may be advancing toward regulatory submission. Definium Reports Positive Late-Stage Anxiety Study
• Neutral Sentiment: The stock’s strong rally has increased expectations for DT120 and may lead to heightened volatility as investors await additional trial details, regulatory steps and the company’s planned September catalyst.
• Negative Sentiment: Definium remains loss-making, and HC Wainwright reduced several EPS forecasts. The firm lowered its FY2026 estimate to a loss of $3.05 per share from $2.10 and cut FY2027, FY2028, FY2029 and FY2030 projections. These revisions highlight continued development costs and the risk that profitability remains several years away.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its position in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Definium Therapeutics in the 3rd quarter valued at approximately $126,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after buying an additional 2,079 shares in the last quarter. Finally, Scientech Research LLC purchased a new stake in shares of Definium Therapeutics in the third quarter valued at approximately $286,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Price Performance

The stock has a fifty day moving average of $39.45 and a two-hundred day moving average of $26.71. The stock has a market cap of $4.38 billion, a price-to-earnings ratio of -12.80 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities research analysts anticipate that Definium Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.